TL;DR
This systematic review and meta-analysis of 17 studies found that upper tract urothelial carcinomas (UTUC) located in the ureter are associated with significantly worse long-term oncological outcomes (cancer-specific survival, overall survival, and disease-free survival) compared to those in the renal pelvis. These findings suggest a need for closer follow-up and consideration of perioperative chemotherapy for patients with ureteral UTUC.
What Problem Does This Paper Address?
Upper tract urothelial carcinoma (UTUC) is a relatively rare cancer, accounting for only 5-10% of all urothelial neoplasms. While radical nephroureterectomy (RNU) is the standard treatment for high-risk UTUC, predicting long-term outcomes remains a challenge. Various factors, such as tumor stage, grade, and lymphovascular invasion, are known prognostic indicators. However, the impact of the primary tumor's location within the upper urinary tract (renal pelvis vs. ureter) on these long-term outcomes has been controversial. Previous studies have yielded conflicting results, necessitating a comprehensive review to clarify this relationship and inform clinical decision-making.
Methods
The researchers conducted a systematic review and meta-analysis following the PRISMA guidelines. They searched four major databases (PubMed, Web of Science, Scopus, and Cochrane Library) for relevant studies published up to October 2021. The primary outcome of interest was cancer-specific survival (CSS), with overall survival (OS) and disease-free survival (DFS) as secondary outcomes. They extracted hazard ratios (HRs) and 95% confidence intervals (CIs) from eligible studies. Statistical analysis involved using random-effect models to pool data, accounting for heterogeneity between studies. Subgroup analyses were performed to explore potential sources of this heterogeneity, including the definition of primary tumor location and geographical region.
Datasets
This study did not introduce new datasets. Instead, it synthesized data from 17 previously published studies that included a total of 16,836 patients with UTUC. These studies were primarily retrospective cohort studies.
Key Insights and Ideas
- Ureteral Location is a Significant Negative Prognostic Factor: The most striking finding is the consistent association between ureteral UTUC and worse oncological outcomes across CSS, OS, and DFS. This suggests that the anatomical differences between the renal pelvis and ureter play a crucial role in disease progression.
- Potential Explanations for Worse Outcomes in Ureteral UTUC: The paper speculates on several reasons for this disparity:
- Anatomical Barriers: The renal pelvis and surrounding tissues may offer better natural barriers against tumor spread compared to the thinner periureteral layer.
- Positive Surgical Margins: Ureteral tumors might be more prone to positive surgical margins during RNU, leading to higher recurrence rates.
- Lymphovascular Invasion (LVI): The thin, vascularized wall of the ureter might facilitate easier spread of cancer cells via LVI.
- Histopathological Factors: While not the primary focus, the paper acknowledges that differences in factors like concomitant CIS (carcinoma in situ) or tumor grade could also contribute, though the data suggests location is independently significant.
- Geographical Differences Matter: Subgroup analyses revealed that the worse prognosis for ureteral UTUC was primarily observed in Asian and European populations, but not in North American populations. This highlights the potential influence of environmental factors (e.g., aristolochic acid exposure in Asia) or genetic predispositions.
- Definition of Location Matters: The way "primary tumor location" was defined across studies (e.g., dominant tumor vs. strictly ureteral/pelvic) influenced the heterogeneity of results, though the overall trend of worse outcomes for ureteral UTUC persisted.
Key Results
- Cancer-Specific Survival (CSS): Patients with ureteral UTUC had significantly worse CSS (HR: 1.37, 95% CI: 1.19–1.57, p < 0.001) compared to those with renal pelvic UTUC.
- Overall Survival (OS): Ureteral UTUC was associated with significantly worse OS (HR: 1.26, 95% CI: 1.08–1.46, p = 0.003).
- Disease-Free Survival (DFS): Patients with ureteral UTUC had significantly worse DFS (HR: 1.51, 95% CI: 1.20–1.89, p < 0.001).
- Heterogeneity: Significant between-study heterogeneity was observed for all outcomes, necessitating the use of random-effect models. Subgroup analyses helped explain some of this heterogeneity, particularly related to geographical location and definition of tumor location.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Nature: All included studies were retrospective, introducing inherent biases.
- Inconsistent Reporting: Data on factors like RNU approach (open vs. laparoscopic), bladder cuff excision, concomitant CIS, LVI, and adjuvant chemotherapy were not uniformly reported, limiting detailed subgroup analyses.
- Confounder Adjustments: The methods for adjusting for confounders in Cox regression analyses varied across studies.
- Limited Data for Subgroup Analyses: Some subgroup analyses were based on a small number of patients, requiring careful interpretation.
The authors emphasize the need for further prospective studies to confirm these findings and to investigate the role of perioperative chemotherapy and more stringent follow-up schedules for patients with ureteral UTUC. They also suggest that the anatomical location of UTUC should be considered as a potential clinical factor for treatment decisions.
Summary updated